Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
about
In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesRapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in KabulA secondary wave of neutrophil infiltration causes necrosis and ulceration in lesions of experimental American cutaneous leishmaniasisImmune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependentChronic Gastrointestinal Nematode Infection Mutes Immune Responses to Mycobacterial Infection Distal to the Gut.Inhibition of caspase-8 activity promotes protective Th1- and Th2-mediated immunity to Leishmania major infection.Macrophages and neutrophils cooperate in immune responses to Leishmania infection.FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious controlPathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis.Permissive and protective roles for neutrophils in leishmaniasis.Differential Activation of Human Keratinocytes by Leishmania Species Causing Localized or Disseminated Disease.Activity of synthetic chalcones in hamsters experimentally infected with Leishmania (Viannia) braziliensis.Proteome profiling of human cutaneous leishmaniasis lesion.
P2860
Q28482212-87637073-DDFB-40A1-B718-E17085EDEE01Q28539775-2F28D50A-8C90-4EFE-B05C-FE90D196C8ABQ33773256-9979F530-5A11-4AC6-8903-55EE2388C00FQ35175936-B2F6627F-2E60-4EC1-971C-BC025F81AEB9Q36597276-6FCA75AC-E0C8-4CA0-95E3-0A7896F95382Q37496769-B4CDBFD4-81CA-4F36-A640-A8F0EE135821Q37849184-689ADC86-075A-44FD-8B79-DD01BD06746EQ38020837-7C4CFB27-D98E-4E44-AA46-59FCD4B47E71Q38180374-AE2CBB13-FDE0-4D9E-9FC9-BB0B912BFEC5Q38195310-8005F901-EFDA-4F2C-85C5-3BC88C993F0AQ38412949-6AB90987-7946-473B-A5DB-1C9AF88ACFB0Q38540870-1A211B3F-F767-41EE-AD9C-D3A3E259EEE5Q38710622-345EEC6B-3420-46D3-A5A7-A34060585A29Q41147459-9EF5BAD6-A73F-4E4C-A31B-91DD821C950AQ41744907-76034D9A-6CB1-40DF-B2EF-E3D71683EF59
P2860
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@ast
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@en
type
label
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@ast
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@en
prefLabel
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@ast
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@en
P2093
P2860
P50
P1476
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
@en
P2093
Abraham Asseffa
Befekadu Lemu
Dawit Wolday
Geremew Tasew
Hailu Meless
Hideo Yagita
Sven Britton
Thorsten Lieke
P2860
P356
10.1371/JOURNAL.PNTD.0000844
P407
P577
2010-10-12T00:00:00Z